Report Overview

The global Gene Therapy for Hemophilia market size is projected xx billion in 2019 and expected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Gene Therapy is expected to witness fast growth owing to the rigorous Research and Development in the respective field and is expected to grow at the CAGR of 5.04% during the forecast period. Gene therapy is expected to be a significant treatment option for individuals during the forecast period. Many pharmaceutical companies are making progress for generating gene therapy for Hemophilia. The final goal of hemophilia gene therapy is the restoration of a corrected gene for the rest of the life of the patient which is a challenging and yet not accomplished. Hemophilia gene therapy treatment has a low brink for success. Moreover, hemophilia gene therapy is more likely to interact with the immune system if the doses are increased. The scientists and the biopharmaceutical industries are trying their best to cure Hemophilia A and B by gene therapy.



Market Drivers

Increase in funding for R&D activities pertaining to gene therapy and rise in awareness regarding gene therapy are the major factors that drive the global gene therapy market growth. In addition, increase in government support for research in gene therapy, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer boost the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the growth of the gene therapy market. On the contrary, untapped potential for emerging markets are expected to provide significant profitable opportunities for the manufacturers in the gene therapy industry.